Rilonacept in cryopyrin-associated periodic syndromes: The beginning of longer-acting interleukin-1 antagonism

Nature Clinical Practice Rheumatology

Volumn 5, Issue 1, 2009, Pages 14-15

  Church, Leigh D ^a   McDermott, Michael F ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACZ 885; CANAKINUMAB; CRYOPYRIN; GENE PRODUCT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONOCLONAL ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; UNCLASSIFIED DRUG;

ARTICLE; AUTOINFLAMMATORY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CRYOPYRIN ASSOCIATED PERIODIC SYNDROME; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GOUT; HUMAN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LOADING DRUG DOSE; MUTATIONAL ANALYSIS; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SYMPTOM; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 58049194057     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0959     Document Type: Article

References (9)

1. Hawkins PN et al. (2003) Efficacy of interleukin-1 receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 348: 2583-2584
2. Hoffman HM et al. (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364: 1779-1785
3. Ratner M (2008) IL-1 trap go-ahead. Nat Biotechnol 26: 485
4. Hoffman HM et al. (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum 58: 2443-2452
5. Goldbach-Mansky R et al. (2008) A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58: 2432-2442
6. Taylor PC (2003) Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr Pharm Des 9: 1095-1106
7. Buch MH et al. (2004) Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum 50: 725-728
8. Terkeltaub R et al. (2007) Placebo-controlled pilot study of rilonacept (IL-1 trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis [abstract #L2]. Presented at the American College of Rheumatology Annual Scientific Meeting: 2007 November 6-11, Boston, MA
9. Church LD et al. (2008) Primer: Inflammasomes and interleukin 1β in inflammatory disorders. Nat Clin Pract Rheumatol 4: 34-42